Ultraviolet germicidal irradiation (UVGI) is a disinfection method that, in medical practice, is used in cleaning hospital rooms, operation theaters, and research facilities and laboratories.
Hospital Acquired Infections (HAI) are very prevalent globally, including developed countries. In the survey, published in the New England Journal of Medicine in 2014, conducted in 183 US hospitals with nearly 4% of the patients had HAI. Even European hospitals suffer this from HAI. This has led to an increase in demand for technologies that can eliminate the germs and pathogens effectively. As a result, UVGI technologies have undergone technological advancements in recent years. These factors have hence helped the UVGI market growth.
However, the cost of installation and maintenance of UVGI disinfectants is high. Hence, hospitals with limited resources and budgets are unable to benefit from this technology. This has also hindered the growth of the ultraviolet germicidal irradiation market.
Key Market Trends
The Usage in Hospitals and Surgical Centers is expected to Dominate the Market
Hospital-acquired Infections (HAI) are highly prevalent in hospitals and surgical centers. According to the Journal of clinical infectious disease, 2017, out of the 5,415 patients surveyed in the hospitals of Singapore, 646 patients, accounting for 11.9%, had 727 distinct HAIs. The burden of HAIs in more developed regions, like Europe, is enormous too. A report published in the Public Library of Science (PLOS) Medicine journal, in 2016, estimated that 2,609,911 new cases of HAI occur every year in the European Union and European Economic Area (EU/EEA). Moreover, the incidence of HAI increases with age. As the global geriatric population is rising (the United Nations report, World Population Aging 2017), the frequency of HAI is also expected to increase.
Continuous protection from ultraviolet germicidal irradiation technologies can reduce airborne bacteria, which can help lower the number of HAIs, including those caused by contact pathogens. Reduced infections result in lessened morbidity and lower costs for both the and the patient. As a result of these benefits, the demand for UVGI instruments has increased, which is expected to help the growth of the ultraviolet germicidal irradiation market.
North America is Expected to Dominate the Market
In North America, the rate of hospital-acquired infection (HAI) is high and is understated as per many researchers. In Canada, there are rising cases of hospital-acquired infections. According to the estimates of the Canadian Nosocomial Infection Surveillance Program (CNISP), 1 in 217 patients acquired an infection while in hospital in 2017. According to a 2017 report by Hospital CMQ, in Mexico, the rate of HAIs in hospitals is between 2.1% and 15.8%.
However, North American countries of the United States (US) and Canada have a developed and well-structured health care system. These systems also encourage research and development. These policies encourage global players to enter the United States and Canada. As a result, these countries enjoy the presence of many global market players. As high demand is met by the presence of global players in the region, the market is further expected to increase.
The global key players are manufacturing the majority of the ultraviolet germicidal irradiation instruments. Market leaders with more funds for research and a better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing the emergence of some small players due to the rise of awareness. This has also helped the ultraviolet germicidal irradiation market grow.
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
1.2 Study Assumptions
1.3 Scope of the Study
4.2 Market Drivers
4.2.1 Increasing Prevalence of Hospital-acquired Infection
4.2.2 Technological Advancements in Ultraviolet Germicidal Irradiation
4.3 Market Restraints
4.3.1 Limitations Associated with Ultraviolet Germicidal Irradiation (UVGI)
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.1 Air Disinfectant
5.1.2 Surface Disinfectant
5.1.3 Other Types
5.2 By End User
5.2.1 Hospitals and Surgical Centers
5.2.2 Research Laboratories
5.2.3 Other End Users
5.3.1 North America
220.127.116.11 United States
18.104.22.168 United Kingdom
22.214.171.124 Rest of Europe
126.96.36.199 South Korea
188.8.131.52 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
184.108.40.206 South Africa
220.127.116.11 Rest of Middle-East and Africa
5.3.5 South America
18.104.22.168 Rest of South America
6.1.1 American Ultraviolet
6.1.2 Angioscore Ltd
6.1.4 Atlantic Ultraviolet Corporation
6.1.6 GENERAL ELECTRIC COMPANY
6.1.7 Koninklijke Philips NV
6.1.8 UltraViolet Devices
6.1.9 Volcano Corporation
A selection of companies mentioned in this report includes:
- American Ultraviolet
- Angioscore Ltd
- Atlantic Ultraviolet Corporation
- GENERAL ELECTRIC COMPANY
- Koninklijke Philips NV
- UltraViolet Devices
- Volcano Corporation